Glucose as a prognostic factor in ovarian carcinoma

Cancer

Volumn 115, Issue 5, 2009, Pages 1021-1027

  Lamkin, Donald M ^b   Spitz, Douglas R ^c,d   Shahzad, Mian M K ^e,f   Zimmerman, Bridget ^a   Lenihan, Daniel J ^f   Degeest, Koen ^c,d   Lubaroff, David M ^a,c,d,g   Shinn, Eileen H ^f   Sood, Anil K ^f   Lutgendorf, Susan K ^a,b,c,d  

^a UNIVERSITY OF IOWA   (United States)

^b University of Iowa   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Glucose; Ovarian cancer; Prognosis; Recurrence; Survival rate

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BIOLOGICAL MARKER; GLUCOSE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; DISEASE FREE INTERVAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; BLOOD GLUCOSE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 61449245594     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24126     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, er al. Cancer statistics, 2008. CA Cancer J Clin. 2007;58:71-96.
2. Chen T, Pcngernze Y, Taylor CC. Src inhibition enhances pacliraxcl cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther. 2005;4:217-224.
3. Markmann S, Gerber B, Briese V. Prognostic value of Ca 125 levels during primary therapy. Anticancer Res. 2007;27: 1837-1840.
4. Park SM, Lim MK, Shin SA, et al. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National health insurance corporation study. J Clin Oncol. 2006;24:5017-5024.
5. Ali NA, O'Brien JM, Blum W, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110:96-102.
6. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179-1185.
7. Krone CA, EIy JTA. Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther. 2005;4:25-31.
8. Rudlowski C, Moser M, Becker AJ, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology. 2004;66:404-410.
9. Canruaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma. Cancer. 2001;92:1144-1150.
10. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001;24:775-778.
11. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care. 2007;30(suppl):S4-S41.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete data. J Amer Stat Assc. 1958;53:457-481.
13. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-202.
14. Van Canter E, Polonsky KS, Scheen AJ. Roles of arcadian rhythmicity and sleep in human glucose regulation. Endocr Rev. 1997;18:716-738.
15. Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, NY: Oxford University Press; 2003.
16. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment, and outcomes of cancer. Nat Clin Pract Oncol. 2005;2:48-53.
17. Warburg O. The Metabolism of Tumors. London: Constable Press; 1930.
18. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63:3847-3854.
19. Weber G. The enzymology of cancer cells (second of two parts). N Eng J Med. 1977;296:541-551.
20. Maity A, Tuttle S. 2-deoxyglucose and radiosensitization: teaching an old dog new tricks? Cancer Biol Ther. 2006;5:824-826.
21. Weihua Z, Tsan R, Huang W, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008;13:385-393.
22. Spitz DR, Sim JE, Ridnour LA, et al. Glucose deprivationinduced oxidative stress in human tumor cells: a fundamental defect in metabolism? Ann NY Acad Sci. 2000;899:349362.
23. 2 mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells. J Biol Chem. 2005;280:4254-4263.
24. Andringa KK, Coleman MC, Aykin-Burns N, et al. Inhibition of glutamate cysteine ligase (GCL) activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose. Cancer Res. 2006;66:1605-1610.
25. -, oxidative stress, and genomic instability. Cancer Res. 2006;66:76l 5-7620.
26. Simons AL, Ahmad IM, Mattson DM, et al. 2-deoxy-Dglucose (2DG) combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67:3364-3370.
27. Fruehauf JP, Meyskens FL. Reactive oxygen species: A breath of life or death? Clin Cancer Res 2007;13:789-794.
28. Simons AL, Fath MA, Mattson DM, et al. Enhanced response of human head and neck cancer xenograft tumors to Cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys. 2007:69:1220-1230.
29. Gapsrur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283:2552-2558.
30. Shaw JE, Hodge AM, de Courten, M. et al. Isolated postchallenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia. 1999;42:1050-1054.